ATE326969T1 - Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation - Google Patents

Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Info

Publication number
ATE326969T1
ATE326969T1 AT99923347T AT99923347T ATE326969T1 AT E326969 T1 ATE326969 T1 AT E326969T1 AT 99923347 T AT99923347 T AT 99923347T AT 99923347 T AT99923347 T AT 99923347T AT E326969 T1 ATE326969 T1 AT E326969T1
Authority
AT
Austria
Prior art keywords
apomorphine
premature ejaculation
treat premature
treat
ejaculation
Prior art date
Application number
AT99923347T
Other languages
English (en)
Inventor
Jeremy P W Heaton
Michael A Adams
Original Assignee
Tap Pharmaceutical Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tap Pharmaceutical Prod Inc filed Critical Tap Pharmaceutical Prod Inc
Application granted granted Critical
Publication of ATE326969T1 publication Critical patent/ATE326969T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99923347T 1998-05-29 1999-05-28 Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation ATE326969T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/086,630 US6403605B1 (en) 1998-05-29 1998-05-29 Methods for the normalization of sexual response and amelioration of long term genital tissue degradation

Publications (1)

Publication Number Publication Date
ATE326969T1 true ATE326969T1 (de) 2006-06-15

Family

ID=22199842

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99923347T ATE326969T1 (de) 1998-05-29 1999-05-28 Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Country Status (11)

Country Link
US (3) US6403605B1 (de)
EP (2) EP1666040A1 (de)
AR (1) AR019579A1 (de)
AT (1) ATE326969T1 (de)
AU (1) AU764009B2 (de)
CA (1) CA2331387A1 (de)
DE (1) DE69931487T2 (de)
ES (1) ES2268869T3 (de)
HK (1) HK1037517A1 (de)
TW (1) TWI232748B (de)
WO (1) WO1999062502A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
SE0002934D0 (sv) 2000-08-17 2000-08-17 Axon Biochemicals Bv New aporphine esters and in their use in therapy
SE0102036D0 (sv) * 2001-06-08 2001-06-08 Axon Biochemicals Bv Pharmaceutical formulation for the efficient administration of apomorphine, 6aR- (-) -N- Propyl- norapomorphine and their derivatives and pro-drugs thereof
BRPI0409380A (pt) * 2003-04-14 2006-04-18 Vectura Ltd composições farmacêuticas
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
US20050181057A1 (en) * 2004-02-13 2005-08-18 Rosenberg Paul K. Vaginal lubricant
PT1750766E (pt) 2004-05-11 2013-09-30 Emotional Brain Bv Formulações farmacêuticas e suas utilizações no tratamento de disfunção sexual feminina
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion
CA2677690C (en) * 2007-02-12 2012-05-15 James V. Winkler Treatment of comorbid premature ejaculation and erectile dysfunction
WO2008100933A2 (en) * 2007-02-12 2008-08-21 Dmi Biosciences, Inc. Reducing side effects of tramadol
US20110150946A1 (en) * 2008-08-22 2011-06-23 Al-Ghananeem Abeer M Transdermal Delivery of Apomorphine Using Microneedles

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2818855A (en) 1954-02-11 1958-01-07 Anthony P Miller Surgical device
US4127118B1 (en) 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
US4687773A (en) 1983-03-28 1987-08-18 Mclean Hospital (+)-N-N-propylnorapomorphine and selective limbic activity
US4521421A (en) 1983-09-26 1985-06-04 Eli Lilly And Company Treatment of sexual dysfunction
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4640921A (en) 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4801587A (en) 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US4980358A (en) * 1988-04-04 1990-12-25 George D. McAdory Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function
US5242391A (en) 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5270323A (en) 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5324718A (en) 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
ATE290864T1 (de) 1993-03-26 2005-04-15 Franciscus Wilhelmus He Merkus Pharmazeutische zusammensetzungen zur intranasalen verabreichung von dihydroergotamin
DE69514794T2 (de) 1994-04-22 2000-07-27 Pentech Pharmaceuticals Inc Sublinguale dosierungsformen enthaltend apomorphin zur verwendung bei der behandlung von erektiler dysfunktion
EP0714663A3 (de) 1994-11-28 1997-01-15 Lilly Co Eli Potenzierung von Wirkstoffresponz durch Serotonin 1A Rezeptor Antagonisten
TR199800628T2 (xx) 1995-10-13 1998-07-21 Neurosearch A/S 8-Azabisiklo$3.2.1]okt-2-en t�revleri, bunlar�n haz�rlanmas� ve kullan�m�.

Also Published As

Publication number Publication date
DE69931487D1 (de) 2006-06-29
ES2268869T3 (es) 2007-03-16
US20030092725A1 (en) 2003-05-15
TWI232748B (en) 2005-05-21
WO1999062502A3 (en) 2000-06-15
AR019579A1 (es) 2002-02-27
EP1082118A2 (de) 2001-03-14
EP1666040A1 (de) 2006-06-07
DE69931487T2 (de) 2007-05-03
AU764009B2 (en) 2003-08-07
HK1037517A1 (en) 2002-02-15
CA2331387A1 (en) 1999-12-09
US6403605B1 (en) 2002-06-11
EP1082118B1 (de) 2006-05-24
WO1999062502A2 (en) 1999-12-09
US20060281752A1 (en) 2006-12-14
AU4027299A (en) 1999-12-20

Similar Documents

Publication Publication Date Title
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
ATE179610T1 (de) Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
ATE247987T1 (de) Behandlung zur beseitigung von gerüchen
ATE300597T1 (de) Behandlung von geweben
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE326969T1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation
ATE338552T1 (de) Verwendungen von et743 zur behandlung von krebs
DE69841984D1 (de) Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
DE69625877T2 (de) Verwendung von 5-HT1A Rezeptor-Liganden zur Behandlung des Glaukoms
ATE281167T1 (de) Verwendung von makroliden zur behandlung von trockenen augen
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
ATE390474T1 (de) Verwendung von polymerem material zur behandlung harter oberflächen
DE69614264T2 (de) Behandlung von aluminiumartikeln zur erhöhung der einbrennhärtbarkeit
ATE410181T1 (de) Verwendung von intereferon gamma zur behandlung von herzhypertrophie
ATE209891T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung der seborrhoischen dermatitis
ATE270102T1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
DE69913380D1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen
DE60103503D1 (de) Verwendung von fsh zur behandlung von infertilität
ATE270545T1 (de) Verwendung von nmda antagonisten zur behandlung des reizkolons

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties